Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Bajor

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Cancer Immunology Research|February 14, 2015
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic CarcinomaRafael Winograd, Katelyn T Byrne, Rebecca A Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2021
Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I TrialTithi Biswas, Afshin Dowlati, Charles A Kunos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2004
High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortalityPunit D Wadhwa, Pingfu Fu, Omer N Koc, et al.
JCI Insight|September 20, 2016
Lack of immunoediting in murine pancreatic cancer reversed with neoantigenRebecca A Evans, Mark S Diamond, Andrew J Rech, et al.
Frontiers in Oncology|March 11, 2022
Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After SurgeryLauren F Huang, Augustine Hong, Gino Cioffi, et al.
Journal of Immunotherapy and Precision Oncology|January 16, 2025
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 StudyAung Naing, Amit Mahipal, Milind Javle, et al.
Clinical Lung Cancer|June 21, 2022
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET TrialVictor Moreno, Desamparados Roda, Joanna Pikiel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.
Cancers|July 13, 2024
Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal CancerConor D J O'Donnell, Nikolas Naleid, Teerada Siripoon, et al.
Oncoimmunology|October 6, 2018
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanomaDavid L Bajor, Rosemarie Mick, Matthew J Riese, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Cancer Immunology Research|February 14, 2015
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic CarcinomaRafael Winograd, Katelyn T Byrne, Rebecca A Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2021
Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I TrialTithi Biswas, Afshin Dowlati, Charles A Kunos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2004
High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortalityPunit D Wadhwa, Pingfu Fu, Omer N Koc, et al.
JCI Insight|September 20, 2016
Lack of immunoediting in murine pancreatic cancer reversed with neoantigenRebecca A Evans, Mark S Diamond, Andrew J Rech, et al.
Frontiers in Oncology|March 11, 2022
Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After SurgeryLauren F Huang, Augustine Hong, Gino Cioffi, et al.
Journal of Immunotherapy and Precision Oncology|January 16, 2025
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 StudyAung Naing, Amit Mahipal, Milind Javle, et al.
Clinical Lung Cancer|June 21, 2022
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET TrialVictor Moreno, Desamparados Roda, Joanna Pikiel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.
Cancers|July 13, 2024
Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal CancerConor D J O'Donnell, Nikolas Naleid, Teerada Siripoon, et al.
Oncoimmunology|October 6, 2018
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanomaDavid L Bajor, Rosemarie Mick, Matthew J Riese, et al.
Pageof 3